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Introduction: Etanercept is a fusion protein consisting of the soluble portion of the p75-tumor necrosis factor
receptor (TNFR) and the Fc fragment of human IgG1, which is often used for the treatment of patients with
rheumatoid arthritis. F8-IL10 is a human immunocytokine based on the F8 antibody and interleukin-10, which is
currently being investigated in rheumatoid arthritis with promising clinical results. We have aimed at expressing
murine versions of these two fusion proteins, in order to assess their pharmaceutical performance in the
collagen-induced model of rheumatoid arthritis in the mouse.
Methods: Two fusion proteins (termed muTNFR-Fc and F8-muIL10) were cloned, expressed in chinese hamster
ovary (CHO) cells, purified and characterized. Biological activity of muTNFR-Fc was assessed by its ability to inhibit
TNF-induced killing of mouse fibroblasts, while F8-muIL10 was characterized in terms of muIL10 activity, of binding
affinity to the cognate antigen of F8, the alternatively-spliced EDA domain of fibronectin, by quantitative
biodistribution analysis and in vivo imaging. The therapeutic activity of both fusion proteins was investigated in a
collagen-induced mouse model of arthritis. Mouse plasma was analyzed for anti-drug antibody formation and
cytokine levels were determined by bead-based multiplex technology. The association of F8-IL10 proteins with
blood cells was studied in a centrifugation assay with radiolabeled protein.
Results: Both fusion proteins exhibited excellent purity and full biological activity in vitro. In addition, F8-muIL10
was able to localize on newly-formed blood vessels in vivo. When used in a murine model of arthritis, the two
proteins inhibited arthritis progression. The activity of muTNFR-Fc was tested alone and in combination with
F8-huIL10. The chimeric version of F8-IL10 was not better then the fully human fusion protein and showed similar
generation of mouse anti-fusion protein antibodies. Incubation studies of F8-muIL10 and F8-huIL10 with blood
revealed that only the fully human fusion protein is not associated with cellular components at concentrations as
low as 0.2 μg/ml, thus facilitating its extravasation from blood vessels.
Conclusions: The described products may represent useful research tools for the study of the anti-arthritic
properties of TNF blockade and of IL10-based immunocytokines in syngeneic immunocompetent models of
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The therapeutic blockade of proinflammatory cytokines
has revolutionized the treatment of rheumatoid arthritis
(RA), leading to the approval and widespread use of bio-
logics for this indication. The most prominent target is
represented by tumor necrosis factor (TNF), a dominant
cytokine capable of inducing the expression of other
proinflammatory cytokines [1,2]. Infliximab (Remicade™),
a blocking chimeric monoclonal antibody, and etanercept
(Enbrel™), a fusion protein consisting of the soluble por-
tion of the p75-TNF receptor (TNFR) and the Fc fragment
of human IgG1 (hinge, CH2 and CH3 domain), were the
first TNF-specific biological therapeutics to make a sub-
stantial impact for the treatment of RA. Later, adalimumab
(Humira™, a fully human inhibitory antibody), certo-
lizumab pegol (Cimzia™, a PEGylated humanized antibody
Fab′ fragment) and golimumab (Simponi™, also a human
blocking antibody) were approved. Other relevant pro-
inflammatory cytokines include interleukin (IL)-1β
(which is targeted by anakinra, a recombinant form of
the IL-1 receptor antagonist) and IL-6 (whose action is
blocked by tocilizumab, a monoclonal antibody specific
to the IL-6 receptor) [3].
The use of anti-inflammatory cytokines represents an al-
ternative approach for the treatment of RA, but has met
with limited success until now. The most prominent ex-
ample is represented by recombinant human IL-10, which
has shown activity in the collagen-induced model of arth-
ritis [4] and which has been investigated in controlled clin-
ical studies [5]. A good safety profile, but only limited
efficacy, was observed in patients receiving IL-10 (Tenovil™)
for 28 days [6]. A combination of IL-10 and methotrexate
was tested in a multicenter, placebo-controlled, dose-
escalating study. The product was administered at a dose
of 8 μg/kg four times daily or 8 μg/kg three times per
week, with an American College of Rheumatology 20%
(ACR20) improved response in 50% of the patients com-
pared with 63% when treated with 20 μg/kg three times
per week and only 10% in patients receiving placebo as
control. However, American College of Rheumatology
50% (ACR50) improved benefits were less impressive,
which probably led to the discontinuation of clinical devel-
opment activities [5].
We recently reported the use of antibody-cytokine fusion
proteins (immunocytokines) for the treatment of arthritis
in the mouse. Particularly, we have shown that immuno-
cytokines consisting of the L19 antibody or the F8 antibody
(serving as delivery vehicle) and of human IL-10 were able
to inhibit arthritis progression in the murine model of
collagen-induced arthritis [7,8]. The L19 and F8 human
antibodies recognize the alternatively-spliced extra-domain
B(EDB) and extra-domain A(EDA) of fibronectin [9,10], re-
spectively, which are not present in plasma fibronectin and
which are almost undetectable in normal adult tissues. Bothfusion proteins exhibited an ability to selectively localize at
sites of arthritis in vivo and to stain pathological specimens
in immunohistochemistry, while the reactivity to normal
tissues was mainly confined to placenta and to the endo-
metrium in the proliferative phase [8]. Based on these
promising results, the F8-IL10 fusion protein was moved to
a phase Ib clinical trial in patients with RA in combination
with methotrexate. The study is still ongoing, but encour-
aging interim results have been reported [11].
As the combination of TNF blockade and recombinant
IL-10 had previously exhibited encouraging results in
the collagen-induced arthritis model [4], we became in-
terested in studying whether a combination with F8-
IL10 would also exhibit a potent inhibition of disease
progression. For these preclinical studies it would be
preferable to use reagents that display their full activity
in the mouse. The clinically approved antibody-based
products Remicade™, Humira™, Cimzia™ and Simponi™
exhibit little or no activity in the mouse as they display a
much reduced affinity towards murine TNF compared
with human TNF. By contrast, Enbrel™ is frequently
used as a TNF blocker in mouse models of RA as it is
active in blocking both human and murine TNF with
similar activity [12].
A fusion protein consisting of the murine soluble por-
tion of the p75-TNF receptor (amino acids 1 to 257) fused
to murine IgG1 (termed by the authors murine p75-
murine IgG1) has previously been reported in a short
communication [13], but the full amino acid sequence of
the product was not disclosed. The pharmacokinetic
parameters of the murine p75-murine IgG1 fusion protein
were studied in mice and were found to be different in
healthy mice and mice with candidiasis, or compared with
etanercept in humans [14]. No direct pharmacokinetic
comparison between murine p75-murine IgG1 and etan-
ercept was reported in the study.
To study the therapeutic potential of a combination of
TNF blockade and F8-IL10, we here report on the cloning,
expression and characterization of murine versions of
etanercept (murine TNFR-Fc) and of F8-IL10 (F8-
muIL10). The fusion proteins were studied both in vitro
and in vivo. The murine version of etanercept exhibited an
inhibition of arthritis progression when used alone or in
combination with F8-IL10. Also F8-muIL10 inhibited arth-
ritis progression, but not more efficiently than the fully hu-
man F8-IL10 counterpart. The new murine products may
represent useful research tools for the study of TNF block-
ade and targeted cytokine delivery in mouse models of RA
and other inflammatory conditions. Surprisingly, we ob-
served a different ability of F8-muIL10 and of F8-huIL10
to interact with blood cells. Only the fully human fusion
protein was not trapped by cellular components at concen-
trations as low as 0.2 μg/ml, thus facilitating its extravasa-
tion from blood vessels and its disease-targeting activity.
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Cell lines and animals
CHO-S cells (Invitrogen, Zug, Switzerland) were cultured
adherent in RPMI 1640 (Gibco, Zug, Switzerland)
supplemented with 10% fetal bovine serum (Gibco), 2 mM
ultraglutamine (Lonza, Basel, Switzerland) and antibiotics/
antimycotics (Gibco) or in suspension in PowerCHO-2CD
(Lonza) with 8 mM ultraglutamine, HT supplement
(Gibco) and antibiotics/antimycotics in shaker incubators.
Lung murine fibroblasts (CCL-1.3; ATCC, Molsheim
Cedex, France) were cultured adherent in Dulbecco’s modi-
fied Eagle’s medium (Gibco) with 10% fetal bovine serum
and antibiotics/antimycotics. MC/9 cells (murine mast
cells, CRL-8306; ATCC) were cultured according to the
supplier’s protocol in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum, 2 mM
ultraglutamine, 10% rat-T-STIM (BD Becton Dickinson,
Allschwil, Switzerland) and 0.05 mM β-mercaptoethanol
(Gibco). Murine F9 teratocarcinoma cells (CRL-1720;
ATCC) were cultured on 0.1% gelatin-coated tissue flasks
in Dulbecco’s modified Eagle’s medium supplemented with
10% fetal bovine serum and antibiotics/antimycotics. Male
DBA/1J mice were obtained from Janvier (Le Genest-
St-Isle, France). Female 129/SvEv mice were obtained from
Charles River (Sulzfeld, Germany).
Cloning of murine fusion proteins
For cloning of muTNFR-Fc the murine TNFR gene
(extracellular domain of TNFRII, amino acids 23 to 258)
was amplified from previously cloned F8(scFv)-TNFRII




C-3′ appending part of a signal sequence at the N-
terminus and an overlapping fragment to muFc at the
C-terminus. The gene for murine Fc (hinge, CH2, CH3;
amino acids 98 to 324) was amplified from a commercial




GG-3′ appending an overlapping fragment to muTNFR
at the N-terminus and a stop codon and NotI restriction
site to the C-terminus. muTNFR and muFc sequences




GGGAGAGG-3′ appending the second part of the sig-
nal sequence and a HindIII restriction site to the N-
terminus. The assembled fragment was double digested
with HindIII/NotI (New England BioLabs, Allschwil,
Switzerland) and ligated into the mammalian cell-expression vector pcDNA3.1(+) (Invitrogen) (for full
sequence see Additional file 1).
F8-muIL10 was cloned using the sequence for F8 in




CCTTGGTCCCTTGGCCGAA-3′ introducing part of a
signal sequence at the N-terminus and part of a C-terminal
(SSSSG)3 linker. The sequence for murine IL10 (amino
acids 19 to 178) was amplified from a commercial cDNA




TG-3′ appending a complementary part of the (SSSSG)3
linker at the N-terminus and a stop codon and NotI restric-
tion site to the C-terminus. F8 diabody and murine IL-10




G-3′ adding the rest of the signal sequence and a NheI
restriction site to the N-terminus. The assembled fragment
was double digested with NheI/NotI (New England BioLabs)
and ligated into the mammalian cell-expression vector
pcDNA3.1(+) (for full sequence see Additional file 2).Expression, purification and characterization of murine
fusion proteins
The fusion proteins were expressed in a stable mono-
clonal cell line as reported before [15]. Briefly, PEI-
mediated transient gene expression [15] was used to
generate a polyclonal batch of protein. An aliquot of the
transient gene expression culture was used to produce a
stable cell line using geneticin (G418, 0.5 g/l; Santa Cruz,
Heidelberg, Germany) for selection. Monoclonal cells
were screened for high expression of protein by ELISA,
using L19-TNFα (produced in our laboratory) as coating
antigen and a goat anti-mouse IgG (Fc-specific)-peroxidase
antibody (Sigma-Aldrich, Buchs, Switzerland) for detection
in the case of muTNFR-Fc. For F8-muIL10, recombinant
EDA was used as antigen and protein A–horseradish per-
oxidase (GE Healthcare, Glattbrugg, Switzerland) for detec-
tion. The best producing clone for each construct was
grown in PowerCHO-2CD medium in suspension for
large-scale production of protein. The proteins were puri-
fied from cell culture supernatant by protein A affinity
chromatography and analyzed by SDS-PAGE, size
exclusion chromatography (Superdex200 10/300GL; GE
Healthcare) and for F8-muIL10 additionally by surface
plasmon analysis (BIAcore) on an EDA-coated CM5 sen-
sor chip (GE Healthcare).
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The biological activity of muTNFR-Fc was determined by
its ability to inhibit TNFα-induced killing of mouse fibro-
blasts [16]. Lung murine fibroblast cells were seeded in a
96-well plate (30,000 cells/well) in 100 μl culture medium
and incubated for 24 hours at 37°C, 5% CO2. Medium
containing actinomycin D (final concentration 2 μg/ml;
Sigma-Aldrich), TNFα (final concentration of trimer 5 pM;
eBioscience, Vienna, Austria) and different concentrations
of muTNFR-Fc (serially diluted from 50 nM to 0.1 pM) was
added to the cells. After incubation at 37°C for 24 hours cell
viability was determined by addition of 20 μl Cell Titer
Aqueous One Solution (Promega, Dübendorf, Switzerland),
and after 2 hours absorption was measured at 490 nm.
For determination of the biological activity of the IL-10
moiety in the F8-muIL10 fusion protein, an IL-4-dependent
proliferation assay of MC/9 cells was used [8]. Cells were
seeded in a 96-well plate (40,000 cells/well) with 200 μl
culture medium (without rat-T-STIM) containing 5 pg
(0.05 units)/ml murine IL-4 (eBioscience) and varying
concentrations of F8-muIL10 or recombinant murine
IL-10 (eBioscience) starting at a concentration of 100 ng/ml
IL-10 equivalents. After incubation at 37°C for 48 hours
20 μl/well Cell Titer Aqueous One Solution was added,
and after 2 hours absorption was measured at 490 nm.
Biodistribution
The in vivo targeting of F8-muIL10 was tested by
quantitative biodistribution analysis using radiolabeled
protein as described before [17]. For this analysis 129/
SvEv mice were implanted subcutaneously (s.c.) with F9
tumor cells (25 × 106 cells) in the flank. Purified
F8-muIL10 (15 μg/mouse) was radioiodinated with 125I and
injected intravenously (i.v.) into the lateral tail vein of mice
(n = 3) grafted with F9 tumors. Mice were sacrificed 24
hours after injection. Organs were excised, weighed and
radioactivity was counted using a Cobra γ counter (Packard
Instrument Company, Meriden, CT, USA). Radioactivity
content of representative organs was expressed as percent-
age of injected dose per gram of tissue.
In vivo imaging
To test the targeting properties of the murine and human
F8-IL10 fusion proteins, a near-infrared fluorescence
imaging study was performed. For this purpose, the pro-
teins (11 nmol F8-muIL10 and F8-huIL10) were incubated
for 1 hour with a 20× molar excess of IRDye 750 N-
hydroxysuccinimidyl ester (220 nmol; LI-COR, Bad
Homburg, Germany) in 10% dimethylsulfoxide/phosphate-
buffered saline (PBS), pH 7.4, at room temperature. Protein
was purified from free dye using a PD10 desalting column
(GE Healthcare), eluted in 5% dimethylsulfoxide/PBS and
concentrated to 1.3 mg/ml using Amicon Ultra (10K) cen-
trifugal filter units (Millipore, Zug, Switzerland). Then 200μg (or 100 μg) of each protein were injected i.v. into the lat-
eral tail vein of mice (n = 1) that had developed arthritis
after the second collagen immunization (see section Mouse
model of collagen-induced arthritis for more details). Mice
were imaged at 1, 4, 24 and 48 hours after the injection
under isoflurane anesthesia on their ventral side using an
IVIS Spectrum machine (Xenogen, Caliper Life Sciences,
Oftringen, Switzerland) with the following imaging para-
meters: λex = 745 nm, λem = 800 nm, exposure time = 1
second, F/stop = 4, small binning. After 48 hours, mice
were sacrificed and paws (arthritic and not affected ones)
were photographed and then submitted to fluorescence im-
aging, using the same parameters.
Mouse model of collagen-induced arthritis
Male DBA/1J mice (8 weeks old) were immunized by sub-
cutaneous injection at the base of the tail with 0.05 ml
emulsion of bovine type II collagen emulsified in Complete
Freund’s Adjuvant (Hooke Laboratories, Lawrence, MA,
USA). Three weeks later, a booster injection of 0.05 ml bo-
vine collagen/Complete Freund’s Adjuvant in the case of
the full collagen induction protocol and 0.04 ml for the re-
duced collagen induction protocol was given to the
mice. After the booster injection, mice were inspected
daily and disease was monitored using two different
scoring systems. To each limb a clinical score was
assigned (0 = normal, 1 = swelling of one or more toes of
the same limb and 2 = swelling of the whole paw). A max-
imum score of eight can be reached in this first scoring sys-
tem [8,18]. A more diverted clinical score, the modified
score, was also used (0 = normal; 1 = one toe inflamed and
swollen; 2 = more than one toe, but not entire paw, in-
flamed and swollen or mild swelling of entire paw; 3 = en-
tire paw inflamed and swollen; 4 = very inflamed and
swollen paw; adapted from Hooke Laboratories). A max-
imum score of 16 can be reached. In addition swelling of af-
fected paws was measured daily with a caliper under
isoflurane anesthesia. Paw thickness is expressed as the
mean of all four paws of each animal. Animals were in-
cluded into a therapy group when showing signs of joint in-
flammation with a score of 1 to 3. When the joint
inflammation was too strong at day 1 (more than one paw,
score >3) mice were not included into the experiment, be-
cause according to our project license (208/2010) we are
not allowed to keep a mouse alive with a conventional arth-
ritic score ≥4 for more than 4 days. All animal experiments
were performed in agreement with Swiss ethical regula-
tions. Ethical approval for all experiments was given by the
state veterinary office (reference number 208/2010;
Veterinäramt des Kantons Zürich, Zürich, Switzerland).
Combination therapy of muTNFR-Fc and F8-huIL10
Mice were immunized according to the full collagen in-
duction protocol. Mice with a new clinical score of 1 to
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group and therapy was started (day 1). Mice received
intravenous injections of muTNFR-Fc (10 μg) into the
lateral tail vein or subcutaneous injections of F8-huIL10
(200 μg) or saline or a combination of muTNFR-Fc (10
μg, i.v.) and F8-huIL10 (200 μg, s.c.), three times on days
1, 4 and 7. Seven mice were analyzed per group in a
daily, nonblinded fashion and the arthritic clinical score,
the thickness of inflamed paws and weight was moni-
tored. Mice were sacrificed at day 5 (PBS), day 8 (F8-
huIL10, muTNFR-Fc) or day 13 (combination) due to
arthritic score (≥4 for more than 4 days with conven-
tional arthritic score) and weight loss (>15%), in accord-
ance with local regulations.
Comparison of F8-huIL10 and F8-muIL10
Mice were immunized according to the reduced col-
lagen induction protocol. Therapy was performed as
described before. Mice received either intravenous injec-
tions of muTNFR-Fc (30 μg) or subcutaneous injections of
F8-huIL10 (200 μg), F8-muIL10 (200 μg) or saline or a
combination of muTNFR-Fc (30 μg, i.v.) and F8-huIL10
(200 μg, s.c.). Ten mice were analyzed per group in a daily,
nonblinded fashion and the arthritic clinical score, the
thickness of inflamed paws and weight was monitored.
Mice were sacrificed at day 8 (PBS), day 9 (F8-huIL10,
muTNFR-Fc, F8-muIL10) or day 13 (combination) due to
arthritic score and weight loss, in accordance with local
regulations.
Detection of anti-F8-huIL10/anti-F8-muIL10 antibodies in
plasma of treated mice
Blood was obtained at the start of the therapy (day 1, n = 4)
from the vena saphena or at the end of therapy from
sacrificed mice through cardiac puncture, processed to
plasma and stored at −20°C. The immunogenicity of F8-
huIL10 and F8-muIL10 was assessed by surface plasmon
resonance (BIAcore 3000) screening of mouse plasma
samples. F8-huIL10 or F8-muIL10 at a concentration of
50 μg/ml were immobilized on a CM5 sensor chip (GE
Healthcare) using an amine coupling kit (GE Healthcare).
Surface density of 2,600 RU and 2,900 RU was achieved
for F8-huIL10 and F8-muIL10, respectively. On a control
flow cell, activation by 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride (EDC) and N-hydroxy-
succinimide (NHS) was performed and immediately
blocked by injecting ethanolamine. For binding analysis,
positive control samples of anti-human IL-10 and anti-
murine IL-10 antibodies (1 and 4 μg/ml; eBioscience) and
serum samples diluted 500-fold in HBS-EP buffer (GE
Healthcare) were passed over the different flow cells with a
flow rate of 30 μl/minute for 3 minutes. The response was
recorded 30 seconds after the end of the injection. The
positive control was run again at the end of the analysis toconfirm binding capacity of the immobilized protein. To re-
generate the surface, 10 mM glycine, pH 2.0, was run over
the flow cells for 40 seconds at 30 μl/minute.
Analysis of cytokine levels in plasma of mice
Blood was obtained at the end of therapy from each mouse
(see above), processed to plasma and stored at −20°C.
To quantify cytokine levels in plasma of treated and
control mice, a multiplex bead-based flow cytometry ana-
lysis was performed using the Mouse Th1/Th2/Th17/
Th22 13plex FlowCytomix Multiplex (eBioscience) fol-
lowing the supplier’s protocol. Fluorescence-activated cell
sorting analysis was performed on a BD FACS Canto (BD
Bioscience, Allschwil, Switzerland) and data evaluated
with FlowCytomix Pro 3.0 software (eBioscience). The
experiment was repeated on a different day in order to
have an independent replicate of the assay (Additional
files 3 and 4). Using standard curves generated by the
FlowCytomix Pro 3.0 software with positive control
samples, a level of quantification was assigned to every
cytokine (Additional files 5 and 6).
Incubation experiment of radiolabeled immunocytokines
with whole blood
The ability of F8-huIL10 and F8-muIL10 to interact with
blood cells was determined by a centrifugation-based assay
with radiolabeled preparations. Purified F8-huIL10 and
F8-muIL10 were radioiodinated with 125I as described
before [17] and different concentrations of labeled protein
were incubated with fresh human and mouse blood.
Human blood was collected in S-Monovette tubes (Kalium-
EDTA (ethylenediamine tetraacetic acid), Sarstedt, Sevelen,
Switzerland) and mouse blood taken from DBA/1J mice via
cardiac puncture after sacrifice using Microtainer LH tubes
(lithium heparin, BD Bioscience) to prevent coagulation.
After 10 minutes of incubation, tubes were centrifuged for 3
minutes at 2,000 × g. Plasma was separated from the cell
pellet and radioactivity of both was counted using a Cobra γ
counter.
Statistical analysis
Data are expressed as the mean ± standard deviation or
standard error of the mean. Differences in arthritic outcome
between therapeutic groups were compared using
GraphPad Prism (GraphPad Software Inc., La Jolla, CA,
USA) grouped two-way ANOVA multiple-comparison
(Bonferroni-corrected) analysis, with P <0.05 considered sig-
nificant. Differences in cytokine levels were compared using
a Mann–Whitney test, with P <0.05 considered significant.
Results
Cloning, expression and characterization of fusion proteins
The murine fusion protein muTNFR-Fc was cloned and



























































Figure 1 Cloning, expression and in vitro characterization of muTNFR-Fc. (a) Schematic representation of the cloning strategy of muTNFR-
Fc. muTNFR was directly fused to the Fc fragment (hinge, CH2 and CH3 regions) of murine IgG1, containing a signal sequence (SS) for secretion
of the protein at the N-terminus. (b) Schematic representation of the formation of a muTNFR-Fc dimer trough disulfide bridges in the hinge
region. (c) SDS-PAGE analysis of purified muTNFR-Fc. M, molecular weight marker; NR, nonreducing conditions; R, reducing conditions. (d) Size
exclusion chromatography (SEC200) of covalent homodimeric muTNFR-Fc. (e) Bioactivity assay of muTNFR-Fc. muTNFR-Fc inhibited tumor necrosis
factor (TNF)-induced killing of mouse fibroblasts with a half-maximal inhibitory concentration of 0.1 nM (mean ± standard deviation, n = 3).
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ine p75-TNF receptor at the N-terminus of a murine IgG1
Fc portion, containing the hinge region (Figure 1a,b). A
complete sequence of muTNFR-Fc is reported in
Additional file 1. The fusion protein was purified from the
culture supernatant by protein A chromatography, yield-
ing a preparation that was pure in SDS-PAGE analysis and
size exclusion chromatography (Figure 1c,d). The bio-
logical activity of muTNFR-Fc was tested by inhibition of
TNF-mediated killing of lung murine fibroblasts [16],
exhibiting a half-maximal inhibitory concentration value
of 0.1 nM (Figure 1e).The production and characterization of the fully human
fusion protein F8-huIL10 have previously been described
by our group [8]. In addition, the fusion protein F8-muIL10
was cloned and expressed by stable transfection in CHO
cells. Murine IL-10 was appended at the C-terminus
of the F8 antibody in noncovalent homodimeric scFv
(diabody) format [10], using a five-amino-acid linker
between variable heavy chain (VH) and variable light chain
(VL), and a 15-amino-acid linker between the antibody
and muIL10 (Figure 2a,b). A complete sequence of
F8-muIL10 is reported in Additional file 2. Also in this



























































































































Figure 2 Cloning, expression and in vitro characterization of
F8-muIL10. (a) Schematic representation of the cloning strategy of
F8-muIL10. The murine IL-10 moiety was fused by a 15-amino-acid
linker (SSSSG)3 to the C-terminus of the F8 scFv antibody fragment
in diabody format (five-amino-acid linker between variable heavy
chain (VH) and variable light chain (VL)). SS, signal sequence. (b)
Schematic representation of protein domain assembly of the
noncovalent F8-muIL10 dimer. (c) SDS-PAGE analysis of purified
F8-muIL10. M, molecular weight marker; NR, nonreducing conditions;
R, reducing conditions. (d) Size exclusion chromatography (SEC200)
of noncovalent homodimeric F8-muIL10. (e) MC/9 cell proliferation
assay. F8-muIL10 and recombinant murine IL10 induced proliferation
of MC/9 cells (mean ± standard deviation (SD), n = 3). (f) BIAcore
analysis of F8-muIL10 on extra-domain A of fibronectin (EDA)-coated
chip. (g) Quantitative biodistribution study of radioiodinated
F8-muIL10. Mice bearing subcutaneous F9 tumors were injected
intravenously with 15 μg radiolabeled protein (n = 3). Mice were
sacrificed after 24 hours and organs were excised and radioactivity
counted, expressing results as percent of injected dose per gram of
tissue (%ID/g ± SD).
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ing a well-behaved protein preparation (Figure 2c,d). The
biological activity of F8-muIL10 was tested by a prolifera-
tion assay on MC/9 cells, as previously described [8]
(Figure 2e). Furthermore, the formation of a high-affinity
and kinetically stable complex between F8-muIL10 and its
cognate antigen (the alternatively spliced EDA domain of
fibronectin) was confirmed by BIAcore analysis (Figure 2f).
In vivo targeting was assessed by quantitative bio-
distribution using radioiodinated F8-muIL10 injected i.v.
into mice bearing subcutaneous F9 tumors. Selective
tumor targeting was seen, with a tumor to blood ratio of
12, but spleen and liver uptake were also high (Figure 2g).
In addition the in vivo targeting properties of F8-
muIL10 and F8-huIL10 were investigated in mice with
collagen-induced arthritis, using near-infrared fluo-
rescence imaging. The fusion proteins, studied at 100 μg
and 200 μg doses after labeling with IRDye 750, were
injected i.v. and mice were imaged 1, 4, 24, and 48 hours
after injection, always using the same acquisition para-
meters. The experiments showed a preferential accumu-
lation of the F8-IL10 fusion proteins in inflamed paws
and toes, which slowly declined over time (Figure 3).
Therapy experiments in the collagen-induced model of
arthritis
The therapeutic activity of muTNFR-Fc and of F8-IL10
proteins (F8-huIL10 and F8-muIL10) was tested in the
collagen-induced model of rheumatoid arthritis in male
DBA/1J mice. In a first experiment, we used a full collagen
induction (0.05 ml emulsion of bovine type II collagen
emulsified in Completes Freund’s Adjuvant and a booster
injection of 0.05 ml of the same emulsion), which led to a
rapid development of the disease. Arthritis severity was
monitored using a conventional arthritic score (1 point for
48h
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Figure 3 In vivo near-infrared fluorescence imaging of F8-IL10 fusion proteins in mice with collagen-induced arthritis. Arthritic mice
(n = 1) were injected intravenously with 200 or 100 μg F8-muIL10 or F8-huIL10 labeled with IRDye 750. (a) Mice injected with 200 μg of fusion
protein were imaged 1, 4, 24 and 48 hours after injection. (b) After 48 hours mice were sacrificed and individual paws were imaged. In addition,
photographs of paws are shown to illustrate the paw swelling. (c) Mice injected with 100 μg fusion protein were imaged 1, 4, and 24 hours after
injection. (d) After 24 hours mice were sacrificed and individual paws were imaged. Indicated numbers represent the score of the according paw:
1, one toe inflamed and swollen; 2, more than one toe, but not entire paw, inflamed and swollen or mild swelling of entire paw; 3, entire paw
inflamed and swollen. FL, front left; FR, front right; BL, back left; BR, back right; plus the according score. *Site of immunization.
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http://arthritis-research.com/content/15/5/R138each limb with at least one affected toe, 2 points if the
whole paw is swollen) and a modified score (1 point if one
toe per limb is affected, 2 points if more than one toe per
limb is affected or a moderate paw swelling is observed, 3
points if the entire paw is swollen, 4 points if the paw is se-
verely swollen). Treatment was started when mice displayed
an arthritic score of 1, 2 or 3 (Figure 4). However, out of 50mice scheduled for treatment, 15 (30%) developed an ex-
plosive disease (moved within 1 day from score 0 to score
>3) and could not be included in the therapy experiment.
The remaining mice were treated with three injections of
saline (s.c.), muTNFR-Fc (10 μg, i.v.), F8-huIL10 (200 μg,
s.c.) or the combination of muTNFR-Fc and F8-huIL10.
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Figure 4 Therapy studies in mice with collagen-induced arthritis. (a) to (d) Mice were immunized according to the full collagen induction
protocol, included in the therapy when showing symptoms and injected on days 1, 4 and 7 (arrows). *Fifteen of 50 mice (30%) developed an
explosive disease and could not be included in the therapy. Mice received saline subcutaneously (s.c.; squares), 200 μg F8-huIL10 s.c. (circles),
10 μg muTNFR-Fc intravenously (i.v.; triangles) or a combination of F8-huIL10 and muTNFR-Fc (crosses). The clinical score was evaluated daily and
expressed as (a) arthritic score or (b) modified arthritic score with mean and standard error of the mean (SEM) of seven mice per group. (c) Paw
swelling was measured daily and paw thickness expressed as the mean of all four paws (mean and SEM). (d) Weight was monitored daily and
expressed as percent of weight loss (mean and SEM). (e) to (h) Mice were immunized according to the reduced collagen induction protocol.
**Six of 60 mice (10%) developed disease too rapidly and could not be included in the therapy. Mice received saline s.c. (squares), 200 μg F8-
huIL10 s.c. (circles), 30 μg muTNFR-Fc i.v. (triangles), a combination of F8-huIL10 and muTNFR-Fc (crosses) or 200 μg F8-muIL10 s.c. (open circles).
(e) Arthritic score or (f) modified arthritic score with mean and SEM of 10 mice per group. (g) Paw swelling was measured daily and paw
thickness expressed as the mean of all four paws (mean and SEM). (h) Weight was monitored daily and expressed as percent of weight loss
(mean and SEM). *1P <0.05, **1P <0.01 combo versus saline; *2P <0.05, **2P <0.01 muTNFR-Fc versus saline; *3P <0.05 combo versus muTNFR-Fc.
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for the combination treatment (P <0.01 vs. saline), whereas
the single agents did not display a significant activity in this
aggressive model of arthritis with full collagen induction
(Figure 4a,b,c).We repeated the experiment using a reduced collagen
induction schedule, featuring a reduced booster injection
(reduction to 80%, 0.04 ml emulsion instead of 0.05 ml).
In this case, only 6/60 mice (10%) could not be included
into the therapy experiment, because they progressed
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s.c.), F8-huIL10 (200 μg, s.c.) and muTNFR-Fc (30 μg,
i.v.; alone or in combination with F8-huIL10) displayed
an inhibition of disease progression compared with sa-
line treatment (Figure 4e,f,g), being statistically signi-
ficant for muTNFR-Fc alone or in combination with
F8-huIL10 compared with saline from day 6 onwards
(P <0.05). Over time, mice lost weight because of arth-
ritis progression, an effect that was reduced by the com-
bination therapy (Figure 4d,h). The administration of
IL-10 fused to an antibody of irrelevant specificity in the
mouse (HyHel10-IL10) has previously been described,
showing inhibition activities that were lower than the
corresponding fusion proteins based on the F8 or L19
antibodies [7,8].
Characterization of mouse plasma
Plasma was collected from mice before the first thera-
peutic injection and when they were sacrificed. We used
BIAcore technology in order to assess whether mice de-
veloped a mouse anti-fusion protein antibody (MAFA)
response as a result of treatment with the fully human
F8-huIL10 or the chimeric F8-muIL10 fusion protein
(Figure 5a,b). Plasma samples were studied at a dilution
of 1:500, whereas monoclonal antibodies specific to hu-
man and murine IL-10 were used as positive controls in
this assay at concentrations of 1 and 4 μg/ml. Plasma
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Figure 5 Analysis of mouse anti-fusion protein antibody response. (a
F8-muIL10 was immobilized on a microsensor chip. Plasma of mice treated
fusion protein or positive control antibodies (anti-huIL10 or anti-muIL10) w
sensor surface was 30 μl/minute for 3 minutes and the response was recor
(RU) of plasma samples and positive controls. Samples were passed over th
F8-muIL10 (grey bars) and binding of mouse anti-fusion protein antibody (not display a detectable BIAcore response, whereas all
samples at the end of treatment revealed the presence of
a MAFA reaction. In this assay, there was no significant
difference between the use of the fully human F8-
huIL10 or of the chimeric F8-muIL10 fusion protein,
suggesting that the main immunogenic contribution in
the mouse was due to the human F8 antibody moiety
(Figure 5c). An assessment of immunogenicity based on
binding velocity on BIAcore chips, rather than on
BIAcore response units at saturation, did not reveal a
substantial difference for the quantification of mouse
anti-fusion protein antibodies (Additional file 7).
Mouse plasma was also used to measure cytokine
levels using a multiplex bead-based assay. The results of
these measurements are reported in Figures 6 and 7,
corresponding to the therapy experiments with full col-
lagen induction and reduced collagen induction. For
each sample and cytokine, measurements were repeated
on a different day in order to have an independent repli-
cate of the assay (Additional files 3 and 4). Using stand-
ard curves defined with positive control samples
(Additional file 5) a level of quantification was assigned
to every cytokine. Most of the measured concentrations
were below the level of quantification, but a significant
increase in the level of IL-27 was observed for F8-
huIL10 and the combination versus saline (P = 0.0017































































) Schematic representation of the BIAcore experiment. F8-huIL10 or
with either the fully human F8-huIL10 or the chimeric F8-muIL10
ere passed over the different flow cells. (b) The flow rate over the
ded 30 seconds after the end of the injection. (c) Relative response
e two different flow cells coated with F8-huIL10 (black bars) or




























































































































































































































































































































































































































































IL-1-alpha IL-2 IL-4 IL-5 IL-6
IL-10 IL-13 IL-17 IL-21 IL-22
IL-27 IFN-gamma TNF-alpha
Figure 6 Analysis of cytokine levels in mice with full collagen-induced arthritis. At the end of the therapy 13 different cytokine
concentrations were measured in plasma using multiplex bead-based flow cytometry. Data points of cytokine concentrations above detection
level are represented in a scatter plot with the mean ± standard error of the mean (n = 7). Standard curves defined with positive control samples
(Additional file 5) were used to generate a level of quantification (LOQ; dotted red line). Most of the measured concentrations were below the
LOQ, but a significant increase in the level of IL-27 was observed for F8-huIL10 and the combination versus saline (*P = 0.0017 and P = 0.038,
respectively). IFN, interferon; IL, interleukin; TNF, tumor necrosis factor.
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Immunocytokines are expected to exert their thera-
peutic activity by extravasation from blood vessels at
sites of disease, followed by antibody binding to its cog-
nate antigen and by a prolonged interaction of the cyto-
kine moiety with leukocytes. Since the binding of IL-10
to its receptor on blood cells could potentially inhibit
extravasation and disease-targeting activity, we mea-
sured the ability of radioiodinated preparations of F8-
huIL10 and F8-muIL10 to interact with blood cells by a
centrifugation-based assay. The two fusion proteins
were incubated with human and murine blood, respect-
ively, for 10 minutes at various concentrations. A cen-
trifugation step followed by radioactivity counting in
plasma and in the cellular pellet allowed one to deter-
mine the fraction of unbound immunocytokine. Figure 8
shows that ~90% of F8-huIL10 is not bound to blood
cells at concentrations as low as 0.2 μg/ml, while F8-
muIL10 revealed ~40% binding to blood at a concentra-
tion of 1 μg/ml.
Discussion
We have described and characterized a murine version of
etanercept and a chimeric version of F8-IL10, whichrepresent useful tools for the preclinical testing of these
two therapeutic modalities, that are based on TNF inhib-
ition and on the targeted delivery of an anti-inflammatory
immunocytokine, respectively.
Murine versions of etanercept have previously been
reported [13,19,20], but these articles did not provide full
information about the cloning, purification and in vitro
characterization of the fusion proteins. Barck and col-
leagues reported that their version of mTNFRII-Fc showed
significant treatment effect in a murine model of collagen-
induced arthritis at a concentration of 1 mg/kg (approxi-
mately 20 μg/mouse), upon analysis of computer-assisted
tomography data [19]. In our study, we see in vivo activity
in the 10 to 30 μg/mouse dose range.
In a first in vivo experiment, we used a full collagen in-
duction protocol (see Methods). This led to a rapid onset
of arthritis, with 30% of the mice developing explosive dis-
ease (that is, moved within 1 day from score 0 to score >3;
excluded from therapy). The mice included in the therapy
experiment showed strong progression in arthritic score,
which was only inhibited by the combination therapy
(F8-huIL10 plus muTNFR-Fc). In contrast to what has been
previously reported by our group in a less aggressive model
of arthritis [8], F8-huIL10 did not show a significant
IL-1-alpha IL-2 IL-4 IL-5 IL-6





























































































































































































































































































































































































































































































































Figure 7 Analysis of cytokine levels in mice with reduced collagen-induced arthritis. At the end of the therapy 13 different cytokine
concentrations were measured in plasma using multiplex bead-based flow cytometry. Data points of cytokine concentrations above detection level are
represented in a scatter plot with the mean ± standard error of the mean (n = 10). Standard curves defined with positive control samples (Additional
file 5) were used to generate a level of quantification (LOQ; dotted red line). IFN, interferon; IL, interleukin; TNF, tumor necrosis factor.
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http://arthritis-research.com/content/15/5/R138therapeutic effect, when used as a single agent. In a second
in vivo experiment the booster injection was reduced to
80%, resulting in a milder development of the disease with
only 10% of the mice excluded from therapy. In this case,
TNF blockade (P = 0.0035), F8-huIL10 (P = 0.0561) and
the combination treatment (P = 0.0023) inhibited arthri-
tis progression upon day 8 when compared with saline

















































Figure 8 Incubation experiment of radiolabeled
immunocytokines with blood, analyzed by a centrifugation-based
assay. (a) Different concentrations of F8-huIL10 were incubated with
fresh human blood. (b) Different concentrations of F8-muIL10 were
incubated with fresh mouse blood. In both cases, inhibitors of
coagulation were used. After a centrifugation step and separation of
plasma from the cell pellet, radioactivity was counted and expressed as
percent of binding.therapeutic activity of targeted IL-10 (for example, F8-
huIL10 or L19-huIL10) is superior to the one of IL-10 fused
to an antibody of irrelevant specificity in the mouse [7,8].
No correlation could be found between treatment groups
and the generation of collagen-specific antibodies (Additional
file 8). Furthermore, within the same mouse, healthy and
inflamed structures could be observed in different paws,
which prevented a homogeneous comparison of leukocyte
infiltration in different treatment groups (Additional file 9).
Since one of the goals of our investigation was the as-
sessment of immunogenic reactions using the fully human
and the chimeric versions of F8-IL10, MAFAs were mea-
sured using BIAcore technology (Figure 5). The results
show that chimerization did not reduce protein immuno-
genicity. Human and murine IL10 share 73% amino acid
identity, whereas an alignment of corresponding germline
V segments of antibody variable genes displays 40 to 80%
amino acid identity between the two species [21-23]. The
variability of CDR3 regions further contributes to se-
quence diversity between human and murine antibodies.
The issue as to whether immunocytokines can be trapped
in blood by cellular components has received some atten-
tion in the past [15,24-26]. Preferably, the immunocytokine
should not bind to leukocytes in blood, as this could pre-
vent its ability to localize on its cognate marker of disease
at extravascular sites. Figure 8 shows a surprising difference
in cellular trapping between F8-huIL10 incubated with
Doll et al. Arthritis Research & Therapy 2013, 15:R138 Page 13 of 15
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This discrepancy may reflect a different abundance of IL10
receptors between mouse and human leukocytes. Reassur-
ingly, the clinical-stage product F8-huIL10 was not blocked
by blood cells at concentrations as low as 0.2 μg/ml.
Dekavil (F8-huIL10) has shown selective targeting of
arthritic lesions and inhibited progression of established
disease in mice with collagen-induced arthritis [8] and is
now being investigated in a phase 1b clinical trial in pa-
tients with arthritis in combination with methotrexate
[11]. The results of this preclinical study provide a ration-
ale for the combined use of Dekavil with TNF blockers, in
line with previous reports about the combination of TNF
blockade and IL-10 [4,27]. Previously, the combined use
of TNF blockade with other anti-inflammatory biological
agents (for example, combination of etanercept with
anakinra) was found to be associated with increased safety
risks in humans, including serious infections (0% for etan-
ercept alone, 3.7 to 7.4% for etanercept plus anakinra), in-
jection site reactions and neutropenia [28].
However, the excellent safety profile of recombinant
human IL10 (Tenovil™) [5] and the fact that no signs of
toxicity were observed in mice treated with muTNFR-Fc
and F8-huIL10 suggest that a combination of etanercept
with Dekavil may indeed be clinically feasible.
Conclusions
The murine analogues of etanercept and of F8-huIL10
represent useful research tools for the study of TNF block-
ade and targeted cytokine delivery in mouse models of RA
and other inflammatory conditions. The results presented in
this study provide a rationale for the combination of Dekavil
with etanercept in patients with RA, who do not respond
sufficiently to either of the two monotherapies. Incubation
studies performed with radiolabeled immunocytokines and
blood indicate that F8-huIL10 is not blocked by leukocytes at
concentrations as low as 0.2 μg/ml and that this product is
thus free to extravasate from blood vessels and to reach its
cognate antigen at sites of disease.
Additional files
Additional file 1: Complete sequence of muTNFR-Fc. The sequence
for murine TNFR (amino acids 23 to 258) was directly fused to the murine
Fc fragment (amino acids 98 to 324), containing the hinge, CH2 and CH3
regions. At the N-terminus a signal sequence (SS) was added. By HindIII
and NotI double digest the insert was included into the mammalian cell-
expression vector pcDNA3.1(+).
Additional file 2: Complete sequence of F8-muIL10. The sequence
for murine IL10 (amino acids 19 to 178) was appended at the C-terminus
of the F8 antibody in diabody format, with a five-amino-acid linker
between variable heavy chain (VH) and variable light chain (VL) and a 15-
amino-acid linker ((SSSSG)3) between the antibody and IL-10. At the
N-terminus a signal sequence (SS) was added. By NheI and NotI double
digest the insert was included into the mammalian cell-expression vector
pcDNA3.1(+).Additional file 3: Replicate of analysis of cytokine levels in mice with
full collagen-induced arthritis. For each sample and cytokine,
measurements were repeated on a different day in order to have an
independent replicate of the assay. At the end of the therapy 13 different
cytokine concentrations were measured in plasma using multiplex
bead-based flow cytometry. Data points of cytokine concentrations above
detection level are represented in a scatter plot with the mean ± standard
error of the mean (n = 7). Standard curves defined with positive control
samples (Additional file 6) were used to generate a level of quantification
(LOQ; dotted red line).
Additional file 4: Replicate of analysis of cytokine levels in mice
with reduced collagen-induced arthritis. For each sample and
cytokine, measurements were repeated on a different day in order to
have an independent replicate of the assay. At the end of the therapy 13
different cytokine concentrations were measured in plasma using
multiplex bead-based flow cytometry. Data points of cytokine
concentrations above detection level are represented in a scatter plot
with the mean ± standard error of the mean (n=10). Standard curves
defined with positive control samples (Additional file 6) were used to
generate a level of quantification (LOQ; dotted red line).
Additional file 5: Standard curves defined with positive control
samples. A mixture of standard cytokines was prepared according to the
supplier’s protocol (eBioscience) and serially diluted. To determine
cytokine concentration, a fluorescence-activated cell sorting analysis was
performed on a BD FACS Canto and data evaluated with FlowCytomix
Pro 3.0 software (eBioscience), generating the standard curves. Manually a
level of quantification (LOQ) was superimposed on these standard curves
(dotted green line).
Additional file 6: Standard curves defined with positive control
samples for the repetition experiment. A mixture of standard cytokines
was prepared according to the supplier’s protocol (eBioscience) and serially
diluted. To determine cytokine concentration, a fluorescence-activated cell
sorting analysis was performed on a BD FACS Canto and data evaluated
with FlowCytomix Pro 3.0 software (eBioscience), generating the standard
curves. Manually a level of quantification (LOQ) was superimposed on these
standard curves (dotted green line).
Additional file 7: Analysis of MAFA response. (a) The flow rate over
the sensor surface was 30 μl/minute for 3 minutes and the initial slope
was calculated using the following equation: (response 60 seconds after
the start of binding – response at baseline) / 60 seconds. (b) Initial slope
of plasma samples and positive controls. Samples were passed over the
two different flow cells coated with F8-huIL10 (black bars) or
F8-muIL10 (grey bars) and the initial slope was calculated. Ab, antibody.
Additional file 8: Anti type-II collagen antibodies. Titers of bovine
type-II collagen-specific total IgG, IgG1 and IgG2a antibodies were
determined using standard ELISA techniques. Briefly, 96-well plates were
coated with 5 μg/ml bovine collagen II solution (Chondrex, Inc., Redmond,
WA, USA) overnight at 4°C. Plasma samples diluted 1:800 were incubated for
1 hour and detected with horseradish peroxidase conjugated anti-mouse
IgG, IgG1 and IgG2a antibodies (Santa Cruz, Heidelberg, Germany). Healthy*,
mice were immunized but did not show any signs of inflammation.
Additional file 9: Immunohistochemical and immunofluorescence
analysis of paw sections. At the end of the therapy, paws from
different therapy groups were frozen in cryoembedding medium (Neg50;
Thermo Scientific, Wohlen, Switzerland) and stored at −80°C for analysis.
(a) Hematoxylin and eosin staining of healthy and inflamed paw. Paw
cryosections (10 μm) were fixed in ice-cold acetone and stained with
hematoxylin solution Gill No. 2 (Sigma Aldrich) and alcoholic eosin Y
solution (Sigma Aldrich). 10× magnification; scale bars = 50 μm. (b)
Immunofluorescence analysis of infiltrating cells. Cryosections (10 μm)
were fixed in ice-cold acetone and immunofluorescence staining was
performed using primary antibodies against the following antigens: rat
anti-mouse CD45 (leukocytes, 1:200; BD Bioscience), rabbit anti-asialo
GM1 (NK cells, 1:4,000; Wako Pure Chemical Industries, Tokyo, Japan), rat
anti-mouse CD4 (CD4+ cells, 1:50; BioXCell, West Lebanon, NH, USA) and
rat anti-mouse CD8 (CD8+ cells, 1:50; BioXCell). Donkey anti-rat
AlexaFluor488 (1:200; Invitrogen) and goat anti-rabbit AlexaFluor488
(1:200; Invitrogen) were used as secondary antibodies for detection.
Doll et al. Arthritis Research & Therapy 2013, 15:R138 Page 14 of 15
http://arthritis-research.com/content/15/5/R138Sections were mounted with fluorescent mounting medium (Dako, Baar,
Switzerland) and analyzed with an Axioskop2 mot plus microscope (Zeiss,
Feldbach, Switzerland). The following scoring system was used for
semiquantitative analysis of infiltrating cells: 0 = negative, 1 = single areas
of positive cells with weak to moderate staining intensity, 2 = single
areas of positive cells with strong staining intensity or disseminated
positivity with weak to moderate staining intensity, 3 = large areas of
positive cells within the whole tissue section with moderate to strong
staining intensity.
10× magnification; scale bar = 50 μm (for all images). (c) Results of
semiquantitative analysis for the different infiltrating cells (n = 2,
F8-muIL10 n = 1). Healthy*, mice were immunized but did not show any
signs of inflammation.Abbreviations
CHO: Chinese hamster ovary; EDA: Extra-domain A of fibronectin;
ELISA: Enzyme-linked immunosorbent assay; i.v.: Intravenously; IL: Interleukin;
MAFA: Mouse anti-fusion protein antibody; PBS: Phosphate-buffered saline;
PCR: Polymerase chain reaction; RA: Rheumatoid arthritis;
rhuIL10: Recombinant human IL10; rmuIL10: Recombinant murine IL10;
s.c.: Subcutaneously; scFv: Single-chain variable fragment; TNF: Tumor
necrosis factor; TNFR: Tumor necrosis factor receptor.
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